Search Results for "Contraceptives"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Contraceptives. Results 71 to 80 of 118 total matches.
Lefamulin (Xenleta) for Community-Acquired Bacterial Pneumonia
The Medical Letter on Drugs and Therapeutics • Sep 23, 2019 (Issue 1581)
who are pregnant. Women of
childbearing potential should use effective contraception during ...
Lefamulin (Xenleta – Nabriva), a semisynthetic
pleuromutilin antibiotic, has been approved by the
FDA for IV and oral treatment of community-acquired
bacterial pneumonia (CABP) in adults. It is the first
systemic pleuromutilin antibiotic to be approved in the
US; retapamulin (Altabax), a 1% topical ointment for
treatment of impetigo, was approved in 2007.
Drugs for Rheumatoid Arthritis
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021 (Issue 1637)
contraceptives can increase serum
concentrations of ethinyl estradiol and levonorgestrel.
Leflunomide can ...
Rheumatoid arthritis (RA) is prevalent in 0.5% of
adults in the US; it is about 2.5 times more common
in women than in men. Guidelines for treatment
of RA from the American College of Rheumatology
were recently updated. The goal of treatment is to
minimize disease activity and prevent irreversible
joint damage.
Expanded Table: Some Conventional DMARDs for Rheumatoid Arthritis (online only)
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021 (Issue 1637)
Persons taking the drug should use
effective contraception while taking
methotrexate and for at least 6 ...
View Expanded Table: Some Conventional DMARDs for Rheumatoid Arthritis
Paxlovid for Treatment of COVID-19
The Medical Letter on Drugs and Therapeutics • Jan 24, 2022 (Issue 1642)
the efficacy of combination
hormonal contraceptives.
PREGNANCY AND LACTATION ― There are no data on
the use ...
On December 22, 2021, the FDA issued an Emergency
Use Authorization (EUA) for the investigational
antiviral drug nirmatrelvir copackaged with the HIV-1
protease inhibitor ritonavir (Paxlovid – Pfizer) for
oral treatment of mild to moderate COVID-19 in
outpatients ≥12 years old who weigh at least 40 kg
and are at high risk of progressing to severe disease,
including hospitalization or death. Paxlovid was the
first oral antiviral drug to be authorized in the US for
treatment of COVID-19; Merck's oral antiviral drug
molnupiravir was granted an EUA for treatment of
COVID-19 on...
Margetuximab (Margenza) for HER2-Positive Breast Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Nov 28, 2022 (Issue 1664)
of reproductive potential should use effective
contraception during treatment with margetuximab
and for 4 months ...
The FDA has approved margetuximab-cmkb
(Margenza – MacroGenics), a HER2/neu receptor antagonist,
for use in combination with chemotherapy
for treatment of metastatic human epidermal growth
factor receptor 2 (HER2)-positive breast cancer in
adults who received ≥2 prior anti-HER2 regimens, at
least one of which was for metastatic disease.
Mirvetuximab Soravtansine (Elahere) for Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022 (Issue 1665)
embryofetal harm. Women
of reproductive potential should use effective
contraception during treatment ...
Mirvetuximab soravtansine-gynx (Elahere – Immuno-Gen), an antibody-drug conjugate, has received
accelerated approval by the FDA for treatment
of folate receptor (FR) alpha-positive, platinum-resistant
epithelial ovarian, fallopian tube, or primary
peritoneal cancer in adults who received 1-3 prior
lines of systemic therapy. Accelerated approval
was based on the overall response rate and median
duration of response.
Fruquintinib (Fruzaqla) for Metastatic Colorectal Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024 (Issue 1696)
partners should use effective contraception during
treatment with fruquintinib and for 2 weeks after ...
Fruquintinib (Fruzaqla – Takeda), an oral kinase
inhibitor, has been approved by the FDA for treatment
of adults with metastatic colorectal cancer (mCRC)
who received prior fluoropyrimidine-, oxaliplatin-, and
irinotecan-based chemotherapy, anti-VEGF therapy,
and, in patients with RAS wild-type mutations, anti-EGFR therapy. The drug can be used in patients with
mCRC regardless of biomarker status. Fruquintinib
is the first drug to become available in the US for
treatment of mCRC that targets 3 VEGF receptor
kinases.
Med Lett Drugs Ther. 2024 Feb 19;66(1696):e34-5 doi:10.58347/tml.2024.1696f | Show Introduction Hide Introduction
Ciltacabtagene Autoleucel (Carvykti) for Multiple Myeloma (online only)
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022 (Issue 1663)
potential were instructed to use a barrier method of
contraception for one year after infusion of the drug ...
The FDA has approved ciltacabtagene autoleucel
(Carvykti – Janssen), a B-cell maturation antigen
(BCMA)-directed genetically-modified cellular product,
for treatment of relapsed or refractory
multiple myeloma in adults who received ≥4 prior
lines of therapy, including a proteasome inhibitor,
an immunomodulatory drug, and an anti-CD38
monoclonal antibody. Carvykti is an individualized
cellular product prepared from the patient's own
T cells, which are genetically modified to express
chimeric antigen receptors (CAR) and then infused
back into the patient. Idecabtagene...
Opdualag for Metastatic Melanoma (online only)
The Medical Letter on Drugs and Therapeutics • Jan 23, 2023 (Issue 1668)
at the
recommended dose. Women of reproductive potential
should use effective contraception during treatment ...
Opdualag (BMS), a fixed-dose combination of two
immune checkpoint inhibitors — nivolumab (Opdivo),
a programmed death receptor-1 (PD-1) inhibitor, and
relatlimab-rmbw, a lymphocyte-activation gene-3
(LAG-3) blocking antibody — has been approved by
the FDA for treatment of unresectable or metastatic
melanoma in patients ≥12 years old. Relatlimab, which
is only available in combination with nivolumab, is
the first LAG-3 blocking antibody to become available
in the US. Immune checkpoint inhibitors, including
the anti-CTLA-4 antibody ipilimumab (Yervoy) and
the PD-1 inhibitors...
Med Lett Drugs Ther. 2023 Jan 23;65(1668):e19-20 doi:10.58347/tml.2023.1668g | Show Introduction Hide Introduction
In Brief: Expanded Heart Failure Indication for Dapagliflozin (Farxiga)
The Medical Letter on Drugs and Therapeutics • Jun 26, 2023 (Issue 1679)
may improve efficacy.
7. EG Raymond et al. Contraception 2023; 121:109998 ertugliflozin Steglatro ...
The sodium-glucose cotransporter 2 (SGLT2)
inhibitor dapagliflozin (Farxiga – AstraZeneca) was
approved by the FDA in 2020 to reduce the risk of
cardiovascular death and hospitalization for heart
failure (HF) in adults with heart failure with reduced
ejection fraction (HFrEF). The indication has now
been expanded to include a reduction in the risk
of urgent HF visits and use in adults with any left
ventricular ejection fraction (LVEF).
Med Lett Drugs Ther. 2023 Jun 26;65(1679):101-2 doi:10.58347/tml.2023.1679c | Show Introduction Hide Introduction